← Holders
Foresite Capital Management VI LLC
What Foresite Capital Management VI LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2013341 · Filed Nov 16, 2026
- Positions
- 22
- Reported value
- $566.4M
- Opened
- 4
- Closed
- 5
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$258.9M12 positions
- Dec 31, 2025$330.8M12 positions
- Mar 31, 2026$460.3M17 positions
- Jun 30, 2026$642.6M23 positions
- Sep 30, 2026$566.4M22 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
CGONCG Oncology, Inc. | 2.1M | −11.0% | $149.5M | 26.4% |
KRSAKorsana Biosciences, Inc. | 1.4M | New | $45.8M | 8.1% |
LTGOLatigo Biotherapeutics, Inc. | 2.2M | New | $36.8M | 6.5% |
SPTXSeaport Therapeutics, Inc. | 1.8M | ±0% | $35.9M | 6.3% |
DNLIDenali Therapeutics Inc. | 1.6M | +15.8% | $33.4M | 5.9% |
PBLSParabilis Medicines, Inc. | 999K | ±0% | $32.3M | 5.7% |
ALMSAlumis Inc. | 4.2M | ±0% | $31.4M | 5.5% |
AGIOAgios Pharmaceuticals, Inc. | 827.1K | +5.4% | $27.5M | 4.9% |
VSTMVerastem, Inc. | 3.1M | ±0% | $25.3M | 4.5% |
GHRSGH Research PLC | 940.5K | ±0% | $22.1M | 3.9% |
CRVSCorvus Pharmaceuticals, Inc. | 1.8M | ±0% | $21.1M | 3.7% |
KYMRKymera Therapeutics, Inc. | 146.3K | ±0% | $16.4M | 2.9% |
AVBPArriVent BioPharma, Inc. | 490.3K | +62.7% | $14.8M | 2.6% |
OBXObsidian Therapeutics, Inc. | 916.1K | New | $12.6M | 2.2% |
JBIOJade Biosciences, Inc. | 886.7K | ±0% | $12.5M | 2.2% |
HNGEHinge Health, Inc. | 108.1K | −51.0% | $10.5M | 1.9% |
AURAAura Biosciences, Inc. | 1.3M | ±0% | $8.4M | 1.5% |
BEAMBeam Therapeutics Inc. | 330K | ±0% | $8.1M | 1.4% |
ZURAZura Bio Ltd | 1.8M | +290.4% | $7.3M | 1.3% |
NERVMinerva Neurosciences, Inc. | 2M | ±0% | $6.7M | 1.2% |
IRONDisc Medicine, Inc. | 68.5K | +6,958.8% | $4.5M | 0.8% |
ENTXEntera Bio Ltd. | 1.2M | New | $3.6M | 0.6% |